Hendrik S. Schaaf

Cape Town, WC, ZA 
Cape Town, WC, ZA 

Overview

Hendrik Schaaf practices practicing medicine in Cape Town, South Africa.

His clinical expertise encompasses Tuberculous Meningitis, Bacterial Meningitis, Pulmonary Tuberculosis, and Meningitis.

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Cape Town, WC, South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period
Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs
Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs
Enrollment Status: Completed
Publish Date: January 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

14 Total Publications

Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis.
Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis.
Journal: The Journal of infectious diseases
Published: March 20, 2026

Frequently Asked Questions about Hendrik S. Schaaf

Is Hendrik S. Schaaf a top-rated expert for Tuberculous Meningitis?

MediFind is an objective health platform that identifies experts based on real-world data. Hendrik S. Schaaf is classified as an Experienced expert for Tuberculous Meningitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hendrik S. Schaaf participate in research or clinical trials?

Yes. Hendrik S. Schaaf has published 14 articles and abstracts on conditions like Tuberculous Meningitis. You can view a list of Hendrik S. Schaaf's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schaaf's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile